BlackRock Fund Advisors’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

BlackRock Fund Advisors’s Portfolio SRNE Stock Details SRNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$3.94M	Buy	804,563 +113,424	+16%	+$681K	﹤0.01%	3007
2016 Q3	$5.35M	Sell	691,139 -55,150	-7%	-$371K	﹤0.01%	2816
2016 Q2	$4.18M	Buy	746,289 +20,587	+3%	+$132K	﹤0.01%	2901
2016 Q1	$3.9M	Sell	725,702 -41,706	-5%	-$242K	﹤0.01%	2865
2015 Q4	$6.68M	Buy	767,408 +20,252	+3%	+$171K	﹤0.01%	2680
2015 Q3	$6.27M	Buy	747,156 +5,510	+0.7%	+$87.8K	﹤0.01%	2666
2015 Q2	$13.1M	Buy	741,646 +683,774	+1,182%	+$8.79M	﹤0.01%	2360
2015 Q1	$669K	Sell	57,872 -3,920	-6%	-$45.4K	﹤0.01%	3240
2014 Q4	$622K	Buy	61,792 +4,410	+8%	+$22.3K	﹤0.01%	3241
2014 Q3	$259K	Sell	57,382 -4,165	-7%	-$22.4K	﹤0.01%	3384
2014 Q2	$415K	Buy	+61,547	New	+$464K	﹤0.01%	3240

Other funds holding SRNE

WCM

Wildcat Capital Management New York $229M AUM 132.65% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Intellectus Partners San Francisco, California $578M AUM 49.48% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

BlackRock Fund Advisors's SRNE Position: Q4 2016 in Review

BlackRock Fund Advisors increased its Sorrento Therapeutics, Inc. (SRNE) stake by 16% in Q4 2016, buying an estimated $681K and bringing the position to 804,563 shares worth $3.94M. The position accounts for ﹤0.01% of the portfolio, ranked #3007.

BlackRock Fund Advisors first reported a position in SRNE in Q2 2014 and has held it in 11 quarters since. The position peaked at $13.1M in Q2 2015. 68 funds tracked by Wall St. Rank hold SRNE as of Q4 2016.

BlackRock Fund Advisors held 804,563 shares of Sorrento Therapeutics, Inc. worth $3.94M as of Q4 2016.
BlackRock Fund Advisors bought 113,424 Sorrento Therapeutics, Inc. shares in Q4 2016, an estimated $681K.
Sorrento Therapeutics, Inc. made up ﹤0.01% of BlackRock Fund Advisors's portfolio in Q4 2016, its #3007 holding.
BlackRock Fund Advisors first reported a position in Sorrento Therapeutics, Inc. in Q2 2014 and has held it in 11 quarters since.
BlackRock Fund Advisors's Sorrento Therapeutics, Inc. position peaked at $13.1M in Q2 2015.
68 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q4 2016.

Based on BlackRock Fund Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.